Skip to main content
SpringerLink
Log in

Removal and inactivation of viruses during the manufacture of a high-purity antihemophilic factor IX from human plasma

  • Articles
  • Published:
Biotechnology and Bioprocess Engineering Aims and scope Submit manuscript

Abstract

The purpose of this study was to evaluate the efficacy and mechanisms of the solvent/detergent (S/D) treatment, DEAE-toyopearl 650M anion-exchange column chromatography, heparin-sepharose 6FF affinity column chromatography, and Viresolve NFP filtration steps employed in the manufacture of high-purity antihemophilic factor IX (Green-Nine VF) from human plasma, with regard to removal and/or inactivation of blood-borne viruses. A variety of experimental model viruses for human pathogenic viruses, including human immunodeficiency virus (HIV), bovine herpes virus (BHV), bovine viral diarrhoea virus (BVDV), hepatitis A virus (HAV), murine encephalomyocarditis virus (EMCV), and porcine parvovirus (PPV), were all selected for this study. Samples from relevant stages of the production process were spiked with each virus and subjected to scale-down processes mimicking the manufacture of high-purity factor IX. Samples were collected at each step, immediately titrated using a 50% tissue culture infectious dose (TCID50), and virus reduction factors were evaluated. S/D treatment using the organic solvent, tri (n-butyl) phosphate (TNBP), and the detergent, Tween 80, was a robust and effective step in inactivation of enveloped viruses. Titers of HIV, BHV, and BVDV were reduced from the initial titer of 6.06, 7.72, and 6.92 log10 TCID50, respectively, reaching undetectable levels within 1 min of S/D treatment. DEAE-toyopearl 650M anion-exchange column chromatography was found to be a moderately effective step in the removal of HAV, EMCV, and PPV with log reduction factors of 1.12, 2.67, and 1.38, respectively. Heparin-sepharose 6FF affinity column chromatography was also moderately effective for partitioning BHV, BVDV, HAV, EMCV, and PPV with log reduction factors of 1.55, 1.35, 1.08, 1.19, and 1.61, respectively. The Viresolve NFP filtration step was a robust and effective step in removing all viruses tested, since HIV, BHV, BVDV, HAV, EMCV, and PPV were completely removed during the filtration step with log reduction factors of ≥ 5.51, ≥ 5.76, ≥ 5.18, ≥ 5.34, ≥ 6.13, and ≥ 4.28, respectively. Cumulative log reduction factors of HIV, BHV, BVDV, HAV, EMCV, and PPV were ≥ 10.52, ≥ 12.07, ≥ 10.49, ≥ 7.54, ≥ 9.99, and ≥ 7.24, respectively. These results indicate that the production process for GreenNine VF has a sufficient virus reduction capacity for achievement of a high margin of virus safety.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O’Connell, N. M. (2003) Factor XI deficiency-from molecular genetics to clinical management. Blood Coagul. Fibrinolysis 14: 59–64.

    Article  Google Scholar 

  2. Berkman, S. A. (1988) Infectious complications of blood transfusion. Blood Rev. 2: 206–210.

    Article  CAS  Google Scholar 

  3. Gröner, A. (2008) Pathogen safety of plasma-derived products — Haemate P/Humate-P. Haemophilia 14: 54–71.

    Article  Google Scholar 

  4. Mosley, J. W. and J. Rakela (1999) Foundling viruses and transfusion medicine. Transfusion 39: 1041–1044.

    Article  CAS  Google Scholar 

  5. Guertler, L. G. (2002) Virus safety of human blood, plasma, and derived products. Thromb. Res. 107: S39–S45.

    Article  CAS  Google Scholar 

  6. Klein, H. G. (2005) Pathogen inactivation technology: cleansing the blood supply. J. Intern. Med. 257: 224–237.

    Article  CAS  Google Scholar 

  7. Tabor, E. (1999) The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39: 1160–1168.

    Article  CAS  Google Scholar 

  8. Bryant, B. J. and H. G. Klein (2007) Pathogen inactivation: the definitive safeguard for the blood supply. Arch. Pathol. Lab. Med. 131: 719–733.

    CAS  Google Scholar 

  9. Robertson, B. H. and D. D. Erdman (2000) Nonenveloped viruses transmitted by blood and blood products. Dev. Biol. Stand. 102: 29–35.

    CAS  Google Scholar 

  10. Laub, R. and P. Strengers (2002) Parvovirus and blood products. Pathol. Biol. (Paris) 50: 339–348.

    CAS  Google Scholar 

  11. Burnouf, T. and M. Radosevich (2000) Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev. 14: 94–110.

    Article  CAS  Google Scholar 

  12. Morgenthaler, J. J. (2000) New development in plasma fractionation and virus inactivation. Vox Sang 78: 217–221.

    Article  Google Scholar 

  13. Powell, J. S., M. Bush, J. Harrison, C. Abildgaard, E. Vosburgh, A. R. Thompson, and D. Hurst (2000) Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80°C terminal dry heat treatment in patients with haemophilia A. Haemophilia 6: 140–149.

    Article  CAS  Google Scholar 

  14. Chandra, S., A. Groener, and F. Feldman (2002) Effectiveness of alternative treatment for reducing potential viral contaminants from plasma-derived products. Thromb. Res. 105: 391–400.

    Article  CAS  Google Scholar 

  15. Shin, J. S., Y. W. Choi, H. M. Sung, Y. W. Ryu, and I. S. Kim (2006) Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment. Biotechnol. Bioprocess Eng. 11: 19–25.

    Article  CAS  Google Scholar 

  16. Kim, I. S., Y. W. Choi, Y. Kang, H. M. Sung, and J. S. Shin (2008) Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma. J. Microbiol. Biotechnol. 18: 997–1003.

    CAS  Google Scholar 

  17. Robinson, S. M., H. Schwinn, and A. Smith (1992) Clotting factors and hepatitis A. Lancet 340: 1465.

    Article  CAS  Google Scholar 

  18. Lawlor, E., S. Graham, E. Davidson, P. L. Yap, C. Cunningham, H. Daly, and I. J. Temperley (1996) Hepatitis A transmission by factor IX concentrates. Vox Sang 73: 189–190.

    Google Scholar 

  19. Chudy, M., I. Budek, B. Keller-Stanislawski, K. A. McCaustland, S. Neidhold, B. H. Robertson, C. M. Nubling, R. Seitz, and J. Lower (1999) A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J. Med. Virol. 57: 91–99.

    Article  CAS  Google Scholar 

  20. Limentani, S. A., K. P. Gowell, and S. R. Deitcher (1995) High-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential. Acta Haematol. 94: 12–17.

    Article  CAS  Google Scholar 

  21. Köhler, M., P. Hellstern, E. Lechler, P. Überfuhr, and G. Müller-Berghaus (1998) Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb. Haemost. 80: 399–402.

    Google Scholar 

  22. Kang, Y., Y. W. Choi, M. S. Hark, K. W. Sohn, J. S. Shin, and I. S. Kim (2008) Industrial-scale production of high-purity antihemophilic factor IX from human plasma. Korean J. Biotechnol. Bioeng. 23: 37–43.

    Google Scholar 

  23. Kim, I. S., Y. W. Choi, Y. Kang, H. M. Sung, K. W. Sohn, and Y.-S. Kim (2008) Improvement of virus safety of an antihemophilic factor IX by virus filtration process. J. Micobiol. Biotechnol. 18: 1317–1325.

    CAS  Google Scholar 

  24. Kim, I. S., Y. W. Choi, and S. R. Lee (2004) Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine. J. Microbiol. Biotechnol. 14: 140–147.

    CAS  Google Scholar 

  25. Bolton, G. R., S. Spector, and D. LaCasse (2006) Increasing the capacity of parvovirus-retentive membranes: performance of the ViresolveTM prefilter. Biotechnol. Appl. Biochem. 43: 55–63.

    Article  CAS  Google Scholar 

  26. Trijzelaar, B. (1993) Regulatory affairs and biotechnology in Europe: III. Introduction into good regulatory practice—validation of virus removal and inactivation. Biotherapy 6: 93–102.

    Article  CAS  Google Scholar 

  27. Celis, P. and G. Silvester (2004) European regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies, and plasma derived medicinal products. Dev. Biol. (Basel) 118: 3–10.

    CAS  Google Scholar 

  28. Farshid, M. (2004) Viral safety evaluation of plasma-derived therapeutic products. Dev. Biol. 118: 11–15.

    CAS  Google Scholar 

  29. Committee for Proprietary Medicinal Products (CPMP), The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit (1996) Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95).

  30. International Conference on Harmonisation (1998) Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability. Federal. Resister 63: 51074–51084.

    Google Scholar 

  31. Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee (2001) Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma. Biotechnol. Bioprocess Eng. 6: 25–30.

    Article  CAS  Google Scholar 

  32. Choi, Y. W. and I. S. Kim (2008) Viral clearance during the manufacture of urokinase from human urine. Biotechnol. Bioprocess. Eng. 13: 25–32.

    Article  CAS  Google Scholar 

  33. Kärber, J. (1931) Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche. Arch. Exp. Path. Pharmak. 162: 480–483.

    Article  Google Scholar 

  34. Aghaie, A., A. A. Pourfatollah, S. Z. Bathaie, S. M. Moazzeni, M. P. H. Khorsand, and Z. Sharifi (2008) Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization. Hum. Antibodies 17: 79–84.

    CAS  Google Scholar 

  35. Roberts, P. L., D. Lloyd, and P. J. Marshall (2009) Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20. Biologicals 37: 26–31.

    Article  CAS  Google Scholar 

  36. Horowitz, M. S., C. Rooks, B. Horowitz, and M. W. Hilgartner (1986) Virus safety of solvent/detergent treated antihaemophiliac factor concentrates. Lancet 2: 186–189.

    Google Scholar 

  37. Prince, A. M., B. Horowitz, and B. Brotman (1986) Sterilization of hepatitis and HTLV III viruses by exposure to Tri-(n-Butyl) phosphate and sodium cholate. Lancet 1: 706–710.

    Article  CAS  Google Scholar 

  38. Horowitz, B., A. Lazo, H. Grossberg, G. Page, A. Lippin, and G. Swan (1998) Virus inactivation by solvent/detergent treatment and the manufacture of SDplasma. Vox Sang 74: 203–206.

    CAS  Google Scholar 

  39. Mannucci, P. M. (1993) Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 64: 197–203.

    Article  CAS  Google Scholar 

  40. Kim, I. S., Y. W. Choi, H. S. Woo, C. E. Chang, and S. Lee (2000) Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VIII concentrate. J. Microbiol. 38: 187–191.

    CAS  Google Scholar 

  41. Josić, D., P. Schulz, L. Biesert, L. Hoffer, H. Schwinn, M. Kordis-Krapez, and A. Strancar (1997) Issues in the development of medical products based on human plasma. J. Chromatogr. B: Biomed. Sci. Appl. 694: 253–269.

    Article  Google Scholar 

  42. Arahana, H. (2001) Viral clearance strategies for biopharmaceutical safety. Part 1: General considerations. Bio. Pharm. 14: 28–35.

    Google Scholar 

  43. Darling, A. (2002) Validation of biopharmaceutical purification processes for virus clearance evaluation. Mol. Biotechnol. 21: 57–83.

    Article  CAS  Google Scholar 

  44. Brorson, K., J. Brown, E. Hamilton, and K. E. Stein (2003) Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J. Chromatogr. A. 989: 155–163.

    Article  CAS  Google Scholar 

  45. Arahana, H. (2001) Viral clearance strategies for biopharmaceutical safety. Part 2: filtration for viral clearance. Bio. Pharm. February: 32–43.

  46. Schmidt, S., J. Mora, S. Dolan, and J. Kauling (2005) An integrated concept for robust and efficient virus clearance and contaminant removal in biotech processes. BioProcess Int. 3: 26–31.

    Google Scholar 

  47. Kim, I. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee (2002) Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7: 340–346.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Sciences and Center for Biopharmaceuticals Safety Validation, Hannam University, Daejeon, 305-811, Korea

    In Seop Kim & Jung Eun Bae

  2. Graduate Program in BT-NT Fusion Science and Technology, Hannam University, Daejon, 305-811, Korea

    In Seop Kim & Hark Mo Sung

  3. Green Cross Corp., Yongin, 449-900, Korea

    Hark Mo Sung, Yong Kang & Yong Woon Choi

  4. Department of Molecular Science and Technology, College of Engineering, Ajou University, Suwon, 443-749, Korea

    Yong Woon Choi

Authors
  1. In Seop Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jung Eun Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hark Mo Sung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong Woon Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to In Seop Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, I.S., Bae, J.E., Sung, H.M. et al. Removal and inactivation of viruses during the manufacture of a high-purity antihemophilic factor IX from human plasma. Biotechnol Bioproc E 14, 716–724 (2009). https://doi.org/10.1007/s12257-009-0167-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12257-009-0167-z

Keywords

Search

Navigation